Evolus to Report Second Quarter 2023 Results and Provide Business Update
19 Julho 2023 - 9:45AM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced that it will report its second quarter 2023 financial
results and provide a business update on Wednesday, August 2, 2023,
after the U.S. financial markets close.
Evolus management will host a conference call and live webcast
to discuss these results at 4:30 p.m. ET that same day. A
question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184
(U.S.) or (201) 389-0877 (international) or connect to the live
webcast via the link on the Investor Relations page of the Evolus
website at www.evolus.com.
Following the completion of the call, a telephonic replay can be
accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415
(international) and using conference number 13739952. An archived
webcast can also be accessed on the Investor Relations page of the
Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Jeuveau® is a registered trademark and Evolysse™ is a trademark
of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718010961/en/
Investor Contact: David K. Erickson
Vice President, Investor Relations Tel: 949-966-1798 Email:
david.erickson@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024